BRONCHIAL ASTHMA: MODERN CONCEPTS OF PATHOGENESIS, DIAGNOSIS AND PERSONALIZED TREATMENT (LITERATURE REVIEW)

Authors

Keywords:

bronchial asthma, chronic airway inflammation, inhaled corticosteroids, biological therapy, personalized medicine.

Abstract

Background: Bronchial asthma is a heterogeneous chronic inflammatory disease of the airways characterized by variable respiratory symptoms, bronchial hyperresponsiveness, and reversible or partially reversible airflow limitation. Despite significant advances in respiratory medicine, asthma remains an important global healthcare problem due to its high prevalence, frequent exacerbations, and substantial impact on patients' quality of life.

Objective: To review current scientific literature concerning the epidemiology, pathogenesis, clinical manifestations, diagnostic approaches, and modern treatment strategies for bronchial asthma, with particular emphasis on personalized and targeted therapy.

Materials and Methods: A narrative review of contemporary scientific publications, international clinical recommendations, and relevant literature on bronchial asthma was conducted. Particular attention was paid to publications addressing immunological mechanisms, airway remodeling, inflammatory biomarkers, pulmonary function assessment, inhaled corticosteroid therapy, and biological agents.

Results: Current evidence demonstrates that bronchial asthma is a multifactorial disease involving complex interactions between genetic predisposition, environmental exposures, airway epithelial dysfunction, immune mechanisms, and inflammatory mediators. Type 2 inflammation plays a major role in many asthma phenotypes and is associated with eosinophilia, increased immunoglobulin E, and elevated levels of interleukins IL-4, IL-5, and IL-13. Modern diagnostic approaches combine clinical assessment, spirometry, bronchodilator reversibility testing, and inflammatory biomarkers. Inhaled corticosteroid-containing regimens remain the foundation of treatment, while biological agents provide additional therapeutic opportunities for patients with severe asthma.

Conclusion: Effective asthma management requires early diagnosis, objective assessment of lung function, identification of inflammatory phenotypes, and individualized treatment. The development of precision medicine and targeted biological therapies represents an important direction for improving disease control and reducing asthma-related complications.

References

1.Reddel H.K.2026 Global Initiative for Asthma Strategy Report: Executive Summary and Key Changes. Am J Respir Crit Care Med. 2026. doi:10.1093/ajrccm/aamag542.

2.Papi A., Brightling C., Pedersen S.E., Reddel H.K.. Asthma. Lancet. 2018;391(10122):783–800.

3.Lambrecht B.N, Hammad H., Fahy J.V. The cytokines of asthma. Immunity. 2019;50(4):975–991.

4.Stern J., Pier J., Litonjua A.A. Asthma epidemiology and risk factors. Semin Immunopathol. 2020;42:5–15.

5.Holguin F., Cardet J.C., Chung K..F. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588.

6.Tiotiu A., Steiropoulos P., Novakova S. Airway remodeling in asthma: mechanisms, diagnosis, treatment, and future directions. Arch Bronconeumol. 2025;61(1):31–40.

7.Gyawali B., Georas S.N, Khurana S. Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev. 2025;34(175):240088.

8.Wechsler M.E. Choosing the right biologic for the right patient with severe asthma. Chest. 2025;167(2):330–342.

9.Kyriakopoulos C., Gogali A., Markozannes G., Kostikas K. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials. Eur Respir Rev. 2024;33(172):230238.

Downloads

Published

2026-11-13